Similar articles

Abstract: The most common medications for the treatment of zoonotic toxoplasmosis are pyrimethamine and sulfadiazine, which may cause serious undesirable side effects. Thus, there is an urgent need to develop novel therapeutics. Baicalein (BAI, C₁₅H₁₀O₅) has been shown to perform well against protozoan parasites including Leishmania and Cryptosporidium. In this study, the inhibition efficacy of BAI on Toxoplasma gondii was evaluated using plaque, invasion, and intracellular proliferation assays. BAI effectively inhibited T. gondii (half-maximum inhibitory concentration (IC₅₀)=6.457×10^-5 mol/L), with a reduced invasion rate (33.56%) and intracellular proliferation, and exhibited low cytotoxicity (half-maximum toxicity concentration (TC₅₀)=5.929×10^-4 mol/L). Further investigation using a mouse model shed light on the inhibitory efficacy of BAI against T. gondii, as well as the potential mechanisms underlying its anti-parasitic effects. The survival time of T. gondii-infected ICR mice treated with BAI was remarkably extended, and their parasite burdens in the liver and spleen were greatly reduced compared with those of the negative control group. Histopathological examination of live sections revealed effective therapeutic outcomes in the treatment groups, with no notable pathological alterations observed. Furthermore, alterations in cytokine levels indicated that BAI not only effectively suppressed the growth of T. gondii but also prevented excessive inflammation in mice. Collectively, these findings underscore the significant inhibitory efficacy of BAI against T. gondii, positioning it as a promising alternative therapeutic agent for toxoplasmosis.

黄芩素作为抗寄生虫药剂在体外和体内对弓形虫的治疗作用

[1]Ben-HarariRR, GoodwinE, CasoyJ, 2017. Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review. Drugs R D, 17(4):523-544.

[2]BiswasA, FrenchT, DüsedauHP, et al., 2017. Behavior of neutrophil granulocytes during Toxoplasma gondii infection in the central nervous system. Front Cell Infect Microbiol, 7:259.

[3]ChanJKC, 2014. The wonderful colors of the hematoxylin-eosin stain in diagnostic surgical pathology. Int J Surg Pathol, 22(1):12-32.

[4]CheraghipourK, MasooriL, EzzatpourB, et al., 2021. The experimental role of medicinal plants in treatment of Toxoplasma gondii infection: a systematic review. Acta Parasitol, 66(2):303-328.

[5]CristaldiC, Saldarriaga CartagenaAM, GanuzaA, et al., 2023. Evaluation of topotecan and 10-hydroxycamptothecin on Toxoplasma gondii: implications on baseline DNA damage and repair efficiency. Int J Parasitol Drugs Drug Resist, 23:120-129.

[6]DaherD, ShaghlilA, SobhE, et al., 2021. Comprehensive overview of Toxoplasma gondii-induced and associated diseases. Pathogens, 10(11):1351.

[7]DaiCS, LiH, WangY, et al., 2021. Inhibition of oxidative stress and ALOX12 and NF-κB pathways contribute to the protective effect of baicalein on carbon tetrachloride-induced acute liver injury. Antioxidants (Basel), 10(6):976.

[8]DanielV, NaujokatC, SadeghiM, et al., 2008. Observational support for an immunoregulatory role of CD3⁺CD4⁺ CD25⁺IFN-γ⁺ blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transpl Int, 21(7):646-660.

[9]DasBB, SenN, RoyA, et al., 2006. Differential induction of Leishmania donovani bi-subunit topoisomerase I–DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I. Nucleic Acids Res, 34(4):1121-1132.

[10]de OliveiraMR, NabaviSF, HabtemariamS, et al., 2015. The effects of baicalein and baicalin on mitochondrial function and dynamics: a review. Pharmacol Res, 100:296-308.

[11]de OliveiraTC, Oliveira SilvaDA, RostkowskaC, et al., 2009. Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo. Exp Parasitol, 122(3):233-241.

[12]Dimier-PoissonI, AlineF, MévélecMN, et al., 2003. Protective mucosal Th2 immune response against Toxoplasma gondii by murine mesenteric lymph node dendritic cells. Infect Immun, 71(9):5254-5265.

[13]DindaB, DindaS, DassharmaS, et al., 2017. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem, 131:68-80.

[14]Djurković-DjakovićO, MilenkovićV, NikolićA, et al., 2002. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J Antimicrob Chemother, 50(6):981-987.

[15]DuKG, LuF, XieCZ, et al., 2022. Toxoplasma gondii infection induces cell apoptosis via multiple pathways revealed by transcriptome analysis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(4):315-327.

[16]EganCE, SukhumavasiW, ButcherBA, et al., 2009. Functional aspects of Toll-like receptor/MyD88 signalling during protozoan infection: focus on Toxoplasma gondii. Clin Exp Immunol, 156(1):17-24.

[17]FicheraME, BhopaleMK, RoosDS, 1995. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother, 39(7):1530-1537.

[18]FoxBA, BzikDJ, 2002. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature, 415(6874):926-929.

[19]GayG, BraunL, Brenier-PinchartMP, et al., 2016. Toxoplasma gondii TgIST co-opts host chromatin repressors dampening STAT1-dependent gene regulation and IFN-γ-mediated host defenses. J Exp Med, 213(9):1779-1798.

[20]HallAO, BeitingDP, TatoC, et al., 2012. The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity, 37(3):511-523.

[21]HaverkosHW, 1987. Assessment of therapy for toxoplasma encephalitis the TE study group. Am J Med, 82(5):907-914.

[22]HeXL, WangYH, GaoM, et al., 2009. Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage. Brain Res, 1249:212-221.

[23]HeXX, WeiZK, ZhouES, et al., 2015. Baicalein attenuates inflammatory responses by suppressing TLR4 mediated NF-κB and MAPK signaling pathways in LPS-induced mastitis in mice. Int Immunopharmacol, 28(1):470-476.

[24]HopperAT, BrockmanA, WiseA, et al., 2019. Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis. J Med Chem, 62(3):1562-1576.

[25]HouJZ, SchindlerU, HenzelWJ, et al., 1994. An interleukin-4-induced transcription factor: IL-4 Stat. Science, 265(5179):1701-1706.

[26]HuQC, ZhangWW, WuZ, et al., 2021. Baicalin and the liver-gut system: pharmacological bases explaining its therapeutic effects. Pharmacol Res, 165:105444.

[27]JiangLP, LiuB, HouSJ, et al., 2022. Discovery and evaluation of chalcone derivatives as novel potential anti-Toxoplasma gondii agents. Eur J Med Chem, 234:114244.

[28]JinZ, MaJB, ZhuG, et al., 2019. Discovery of novel anti-cryptosporidial activities from natural products by in vitro high-throughput phenotypic screening. Front Microbiol, 10:1999.

[29]JohariJ, KianmehrA, MustafaMR, et al., 2012. Antiviral activity of baicalein and quercetin against the Japanese encephalitis virus. Int J Mol Sci, 13(12):16785-16795.

[30]KovacsJA, 1992. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet, 340(8820):637-638.

[31]LagalV, DinisM, CannellaD, et al., 2015. AMA1-deficient Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity. Infect Immun, 83(6):2475-2486.

[32]le GrosG, Ben-SassonSZ, SederR, et al., 1990. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med, 172(3):921-929.

[33]LeeIK, KangKA, ZhangR, et al., 2011. Mitochondria protection of baicalein against oxidative damage via induction of manganese superoxide dismutase. Environ Toxicol Pharmacol, 31(1):233-241.

[34]LiW, GrechJ, StortzJF, et al., 2022. A splitCas9 phenotypic screen in Toxoplasma gondii identifies proteins involved in host cell egress and invasion. Nat Microbiol, 7(6):882-895.

[35]Li-WeberM, 2009. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev, 35(1):57-68.

[36]LiangW, HuangXB, ChenWQ, 2017. The effects of baicalin and baicalein on cerebral ischemia: a review. Aging Dis, 8(6):850-867.

[37]LiuG, LiZF, WeiY, et al., 2014. Direct detection of FoxP3 expression in thymic double-negative CD4^-CD8^- cells by flow cytometry. Sci Rep, 4:5781.

[38]LiuSX, WuMM, HuaQQ, et al., 2020. Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain. Parasit Vectors, 13:242.

[39]LuCX, LiuXY, LiuJ, et al., 2022. Immunocompetent rabbits infected with Cryptosporidium cuniculus as an animal model for anti-cryptosporidial drug testing. Int J Parasitol, 52(4):205-210.

[40]LuoQ, YeJQ, ZengLL, et al., 2017. Elevated expression of TIGIT on CD3⁺CD4⁺ T cells correlates with disease activity in systemic lupus erythematosus. Allergy Asthma Clin Immunol, 13:15.

[41]LuoZ, KuangXP, ZhouQQ, et al., 2020. Inhibitory effects of baicalein against herpes simplex virus type 1. Acta Pharm Sin B, 10(12):2323-2338.

[42]MelchorSJ, EwaldSE, 2019. Disease tolerance in Toxoplasma infection. Front Cell Infect Microbiol, 9:185.

[43]MitchellRE, HassanM, BurtonBR, et al., 2017. IL-4 enhances IL-10 production in Th1 cells: implications for Th1 and Th2 regulation. Sci Rep, 7:11315.

[44]MontazeriM, SharifM, SarviS, et al., 2017. A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006–2016). Front Microbiol, 8:25.

[45]MunozM, LiesenfeldO, HeimesaatMM, 2011. Immunology of Toxoplasma gondii. Immunol Rev, 240(1):269-285.

[46]MuscateF, WoestemeierA, GaglianiN, 2021. Functional heterogeneity of CD4⁺ T cells in liver inflammation. Semin Immunopathol, 43(4):549-561.

[47]NedergaardBS, LadekarlM, ThomsenHF, et al., 2007. Low density of CD3⁺, CD4⁺ and CD8⁺ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br J Cancer, 97(8):1135-1138.

[48]NeyerLE, GrunigG, FortM, et al., 1997. Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii. Infect Immun, 65(5):1675-1682.

[49]OliasP, EtheridgeRD, ZhangY, et al., 2016. Toxoplasma effector recruits the Mi-2/NuRD complex to repress STAT1 transcription and block IFN-γ-dependent gene expression. Cell Host Microbe, 20(1):72-82.

[50]PapanastasatouM, VerykokakisM, 2023. Innate-like T lymphocytes in chronic liver disease. Front Immunol, 14:1114605.

[51]ParkW, JangH, KimHS, et al., 2024. Therapeutic efficacy and anti-inflammatory mechanism of baicalein on endometriosis progression in patient-derived cell line and mouse model. Phytomedicine, 130:155469.

[52]PatwardhanRS, SharmaD, ThohM, et al., 2016. Baicalein exhibits anti-inflammatory effects via inhibition of NF-κB transactivation. Biochem Pharmacol, 108:75-89.

[53]PikettyC, DerouinF, RouveixB, et al., 1990. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother, 34(8):1467-1472.

[54]PlataniasLC, 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol, 5(5):375-386.

[55]PorterSB, SandeMA, 1992. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med, 327(23):1643-1648.

[56]QiZL, YinF, LuLN, et al., 2013. Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production. Inflamm Res, 62(9):845-855.

[57]RathoreAS, KumarS, KonwarR, et al., 2014. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res, 140(3):361-369.

[58]ReslanA, HaddadJG, Moukendza KoundiL, et al., 2021. Zika virus growth in human kidney cells is restricted by an elevated glucose level. Int J Mol Sci, 22(5):2495.

[59]RomandS, PudneyM, DerouinF, 1993. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother, 37(11):2371-2378.

[60]SaitoH, MurataY, NonakaM, et al., 2020. Screening of a library of traditional Chinese medicines to identify compounds and extracts which inhibit Toxoplasma gondii growth. J Vet Med Sci, 82(2):184-187.

[61]SoheilianM, RamezaniA, AzimzadehA, et al., 2011. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology, 118(1):134-141.

[62]SowndhararajanK, DeepaP, KimM, et al., 2017. Baicalein as a potent neuroprotective agent: a review. Biomed Pharmacother, 95:1021-1032.

[63]SwierczynskiB, BessieresMH, CassaingS, et al., 2000. Inhibitory activity of anti-interleukin-4 and anti-interleukin-10 antibodies on Toxoplasma gondii proliferation in mouse peritoneal macrophages cocultured with splenocytes from infected mice. Parasitol Res, 86(2):151-157.

[64]TomuraM, YuWG, AhnHJ, et al., 1999. A novel function of Vα14⁺CD4⁺NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol, 163(1):93-101.

[65]TrinchieriG, 1997. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-γ). Curr Opin Immunol, 9(1):17-23.

[66]WangX, XieL, LongJY, et al., 2022. Therapeutic effect of baicalin on inflammatory bowel disease: a review. J Ethnopharmacol, 283:114749.

[67]WangYJ, HanE, XingQH, et al., 2015. Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells. Cancer Lett, 358(2):170-179.

[68]XinLY, GaoJL, LinHC, et al., 2020. Regulatory mechanisms of baicalin in cardiovascular diseases: a review. Front Pharmacol, 11:583200.

[69]YangXY, HuangB, ChenJP, et al., 2012. In vitro effects of aqueous extracts of Astragalus membranaceus and Scutellaria baicalensis GEORGI on Toxoplasma gondii. Parasitol Res, 110(6):2221-2227.

[70]YarovinskyF, 2008. Toll-like receptors and their role in host resistance to Toxoplasma gondii. Immunol Lett, 119(1-2):17-21.

[71]YunMY, YangJH, KimDK, et al., 2010. Therapeutic effects of baicalein on atopic dermatitis-like skin lesions of NC/Nga mice induced by dermatophagoides pteronyssinus. Int Immunopharmacol, 10(9):1142-1148.

[72]ZengY, SongC, DingX, et al., 2007. Baicalin reduces the severity of experimental autoimmune encephalomyelitis. Braz J Med Biol Res, 40(7):1003-1010.

[73]ZhangJL, SiHF, LiB, et al., 2019. Myrislignan exhibits activities against Toxoplasma gondii RH strain by triggering mitochondrial dysfunction. Front Microbiol, 10:2152.

[74]ZhaoXY, KongDW, ZhouQM, et al., 2021. Baicalein alleviates depression-like behavior in rotenone-induced Parkinson’s disease model in mice through activating the BDNF/TrkB/CREB pathway. Biomed Pharmacother, 140:111556.